Accessed August 15, Prilosec OTC omeprazole information. September 21, Accessed June 5, Novartis launches Prevacid 24HR over-the-counter for true hour frequent heartburn relief. Novartis press releases. November 12, American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.
Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. Flynn A. The role of dietary calcium in bone health. Proc Nutr Soc. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors.
March 28, Accessed June 11, Long-term proton pump inhibitor therapy and risk of hip fracture. Use of proton pump inhibitors and risk of osteoporosis-related fractures. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study CaMos. Proton pump inhibitors: risk of bone fractures. Health Canada. April 4, Accessed August 27, March 14, Proton-pump inhibitor use is associated with low serum magnesium concentrations.
Prevacid OTC should be taken in the morning before you eat breakfast. Read and carefully follow any Instructions for Use provided with your medicine. Ask your doctor or pharmacist if you do not understand these instructions. Shake the oral suspension liquid before you measure a dose. Use the dosing syringe provided, or use a medicine dose-measuring device not a kitchen spoon.
Remove an orally disintegrating tablet from the package only when you are ready to take the medicine. Place the tablet in your mouth and allow it to dissolve, without chewing. Swallow several times as the tablet dissolves. Prevacid OTC should be taken only once daily for 14 days. It may take up to 4 days for full effect.
Allow at least 4 months to pass before you start another day treatment with Prevacid OTC. Call your doctor if your symptoms do not improve or if they get worse while you are taking lansoprazole. If you take Prevacid OTC, call your doctor if your heartburn gets worse over the day treatment, or if you need treatment more than once every 4 months.
Some conditions are treated with a combination of lansoprazole and antibiotics. Use all medications as directed. Store at room temperature away from moisture, heat, and light. Do not freeze the liquid medicine. Do not chew the medication.
Do not prepare doses before the time of administration. Alternatively, the capsule may be emptied into a small volume of either apple juice, orange juice, or tomato juice 60 ml, approximately 2 ounces , mixed briefly and swallowed immediately. To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.
The granules have been shown in vitro to remain intact when exposed to apple, cranberry, grape, orange, pineapple, prune, tomato, and V-8 vegetable juice and stored for up to 30 minutes. Delayed-release disintegrating tablets: Place on the tongue and allow to disintegrate until the particles can be swallowed.
Do not cut, chew, or crush the tablets. For administration via an oral syringe, the tablet can be dissolved in water 4 ml for 15 mg tablet, 10 ml for 30 mg tablet and should be administered within 15 minutes.
Patients with a nasogastric tube: Prevacid capsules or disintegrating tablets can be administered via a nasogastric tube. Capsules: Open the capsule and mix the intact granules in 40 ml of apple juice and inject through the nasogastric tube into the stomach. After administration, flush the nasogastric tube with additional apple juice to clear the tube.
Disintegrating tablets: Dissolve tablet in water 4 ml for 15 mg tablet, 10 ml for 30 mg tablet and administer within 15 minutes. After administration, flush the tube to clear it.
Delayed-release oral suspension: Packets containing the enteric-coated granules 15 or 30 mg doses are mixed with 2 tablespoonfuls 30 ml of water to form a strawberry-flavored suspension intended for immediate administration after mixing. Do not use with other liquids or foods. Stir well and drink immediately. Do not crush or chew the granules. If any material remains after drinking, add more water, stir, and drink immediately. Empty the contents of one 30 mg lansoprazole capsule into an empty 15 ml syringe with needle in place plunger removed.
Then, replace the plunger and uncap the needle. Withdraw 10 ml of sodium bicarbonate 8. Gently shake syringe for 10 to 15 minutes, until the granules dissolve and a white suspension of lansoprazole is obtained. Extended stability data are not available; it is recommended that SLS be used immediately following preparation.
Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. Administer as an intravenous IV infusion. Mix gently by swirling. The reconstituted solution can be held for 1 hour when stored at 25 degrees C 77 degrees F prior to further dilution. Reconstituted vials and admixtures do not need to be protected from light. Do not freeze.
Preparation and Administration of IV infusion Dilute the reconstituted vial in either 50 ml of 0. Store the admixture at 25 degrees C 77 degrees F. No refrigeration is required. If reconstituted with NS or LR, solution must be administered within 24 hours. If reconstituted with D5W, solution must be administered within 12 hours.
Administer using the in-line filter provided. The filter MUST be used to remove precipitate. Administered either through a dedicated line or a Y-site. A dedicated line is not required; however, the IV line should be flushed before and after administration.
When administered via a Y-site, immediately stop use if a precipitation or discoloration occurs. Infuse over 30 minutes. First-Lansoprazole: - Protect from freezing - Protect from light - Store at room temperature between 59 to 86 degrees F - Store reconstituted product in refrigerator between 36 to 46 degrees F for up to 30 days Heartburn Relief: - Store at controlled room temperature between 68 and 77 degrees F Prevacid: - Store at controlled room temperature between 68 and 77 degrees F.
Lansoprazole is contraindicated in patients who have shown lansoprazole hypersensitivity. Lansoprazole is a proton pump inhibitor PPI and should be used with caution in patients with known proton pump inhibitors PPIs hypersensitivity. There has been evidence of PPI cross-sensitivity in some sensitive individuals in literature reports.
Although rare, occasionally such reactions can be serious e. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function e.
There have been reports of patients who were diagnosed on biopsy and in the absence of extra-renal manifestations e. Discontinue lansoprazole and evaluate patients with suspected acute TIN. Daily treatment with gastric acid-suppressing medication such as lansoprazole over a long period of time e. Cases of cyanocobalamin deficiency occurring with acid-suppression therapy have been reported in the literature. One large case-controlled study compared patients with and without an incident diagnosis of vitamin B12 deficiency.
In addition, a dose-dependant relationship was evident, as larger daily PPI pill counts were more strongly associated with vitamin B12 deficiency. The possibility of cyanocobalamin deficiency should, therefore, be considered if clinical symptoms are observed. Lansoprazole elimination half-life is significantly prolonged in patients with hepatic disease. In patients with severe hepatic disease, dosage reduction of lansoprazole should be considered.
Abnormal liver-function tests have been reported infrequently with lansoprazole use. The use of gastric acid suppressive therapy, such as PPIs, may increase the risk of enteric infection by encouraging the growth of gut microflora and increasing susceptibility to organisms including Salmonella, Campylobacter jejuni, Escherichia coli, Clostridium difficile, Vibrio cholerae, and Listeria. A systematic review examined the relationship between PPI use and susceptibility to enteric infections and found enhanced susceptibility for Salmonella infections adjusted RR range: 4.
Advise patients to seek immediate care from a healthcare professional if they experience watery stool that does not go away, abdominal pain, and fever while taking PPIs.
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. The PPIs, including lansoprazole, are recommended for use in combination with certain antibiotics to eradicate Helicobacter pylori. Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening.
Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents in combination with PPIs. Patients are usually asymptomatic and fundic gland polyps are identified incidentally on endoscopy. The risk of fundic gland polyps increases with long term proton pump inhibitor PPI use, especially beyond one year.
Use the shortest duration of PPI therapy appropriate to treat specific condition. Symptomatic response to therapy with lansoprazole does not preclude the presence of gastric cancer or other malignancy. Use proton pump inhibitors PPIs in patients with or who have risk factors for osteoporosis cautiously.
PPIs have been associated with a possible increased risk of bone fractures of the hip, wrist, and spine. Epidemiological studies have reported an increased risk of fractures with the use of PPIs; the studies compared claims data of patients treated with PPIs versus individuals who were not using PPIs. The risk of fracture was increased in patients who received high-dose defined as multiple daily doses or doses greater than those recommended in non-prescription use , and long-term PPI therapy a year or longer ; fractures were primarily observed in adult patients 50 years of age and older.
Pre-approval randomized clinical trials RCTs of PPIs have not found an increased risk of fractures of the hip, wrist, or spine; however, these RCTs were of shorter study duration generally 6 months or less.
When prescribing PPIs, consider whether a lower dose or shorter duration of therapy would adequately treat the patient's condition. In patients with or at risk for osteopenia or osteoporosis, manage their bone status according to current clinical practice, and ensure adequate vitamin D and calcium supplementation. Daily treatment with a gastric acid-suppressing medication over a long period of time e. Generally, hypomagnesemia is corrected with magnesium supplementation; however, in cases where hypomagnesemia is observed during PPI administration, discontinuation of the PPI may also be necessary.
Low serum magnesium may lead to serious adverse events such as muscle spasm tetany , seizures, and irregular heartbeat arrhythmias. In pediatric patients, irregular heartbeat may cause fatigue, upset stomach, dizziness, and lightheadedness. For patients expected to be on PPI therapy for a prolonged period of time, it is prudent for clinicians to obtain serum magnesium concentrations prior to initiating PPI therapy as well as throughout treatment. Patients on concomitant medications such as digoxin or diuretics see Interactions may also require periodic monitoring of serum magnesium.
Studies suggest that long-term PPI therapy is associated with a temporal increase in gastric acid secretion shortly following treatment discontinuation.
A similar and well established response has been noted after withdrawal of H2 blockers. Profound gastric acid suppression during PPI therapy leads to a drug-induced reflex hypergastrinemia and subsequent rebound acid hypersecretion.
In this hypersecretory state, enterochromaffin-like cell hypertrophy also results in a temporal increase in serum chromogranin A CgA levels. It is unclear, however, if this hypersecretory reflex results in clinically significant effects in patients on or attempting to discontinue PPI therapy.
A clinically significant effect may lead to gastric acid-related symptoms upon PPI withdrawal and possible therapy dependence. Studies in healthy subjects H. Until more consistent study results shed light on this possible effect, it is prudent to follow current treatment guidelines employing the lowest effective dose, for the shortest duration of time in symptomatic patients.
For patients requiring maintenance therapy, consider on demand or intermittent PPI therapy, step down therapy to an H2 blocker, and regularly assess the need for continued gastric suppressive therapy.
Available data from published observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole treatment. Animal reproductive studies at doses up to 40 times the recommended human dose based on body surface area, revealed no evidence of impaired fertility or fetal harm. It is not known if lansoprazole crosses the human placenta; its low molecular weight suggests that it has the potential to do so.
Cases of inadvertent exposure and therapeutic use of lansoprazole in early gestation in humans suggest a low risk to the fetus. In a prospective study, outcomes from a group of 62 pregnant women administered median daily doses of 30 mg of lansoprazole were compared to a control group of pregnant women who did not take any PPIs. In a retrospective cohort study covering all live births in Denmark from to , there was no significant increase in major birth defects during analysis of first trimester exposure to lansoprazole in live births.
Animal studies indicate that lansoprazole is excreted into breast milk. No studies have been done to determine if lansoprazole is similarly excreted into human milk. Alternative therapies for consideration include antacids and H2 blockers. Patients with phenylketonuria should be made aware that lansoprazole disintegrating tablets contain phenylalanine 2. The capsule and syrup formulations do not contain phenylalanine. The safety and efficacy of lansoprazole has not been established in neonates or infants; however, the drug has been used off-label with caution in these populations.
A multicenter, double-blind, placebo controlled study including infants 1 month to younger than 1 year of age with symptomatic GERD failed to show safety and efficacy. Limited data are available describing lansoprazole use in neonates. In nonclinical studies in juvenile rats, heart valve thickening and bone changes delayed growth and impairment of weight gain were reported at doses at least 2. Patients one year of age and older do not appear to be at risk of heart valve injury.
Use with caution in patients with a history of systemic lupus erythematosus SLE as lansoprazole has been reported to activate or exacerbate SLE. Administration of lansoprazole may result in laboratory test interference, specifically serum chromogranin A CgA tests for neuroendocrine tumors, urine tests for tetrahydrocannabinol THC , secretin stimulation tests, and diagnostic tests for Helicobacter pylori.
Gastric acid suppression may increase serum CgA. Increased CgA concentrations may cause false positive results in diagnostic investigations for neuroendocrine tumors. To prevent this interference, temporarily stop lansoprazole at least 14 days before assessing CgA concentrations and consider repeating the test if initial concentrations are high. If serial tests are performed, ensure the same commercial laboratory is used as reference ranges may vary.
If a PPI-induced false positive urine screen is suspected, confirm the positive results using an alternative testing method. PPIs may also cause a hyper-response in gastrin secretion to the secretin stimulation test, falsely suggesting gastrinoma. Health care providers are advised to temporarily stop lansoprazole at least 28 days prior to performing a secretin stimulation test to allow gastrin concentrations to return to baseline. Preparations that combine PPIs with antimicrobials and bismuth are known to suppress H.
At a minimum, instruct the patient to avoid the use of lansoprazole in the 1 to 2 weeks prior to the test and the use of antimicrobials and bismuth preparations in the 4 weeks prior to the test. Avoid use for more than 8 weeks except for high-risk patients e. If a PPI is used for longer than 12 weeks, the clinical rationale and documentation for continued use should support an underlying chronic disease e.
Monitor for adverse events, including an increased risk of Clostridium difficile colitis. Acalabrutinib: Major Avoid the concomitant use of acalabrutinib and proton pump inhibitors PPI , such as lansoprazole; decreased acalabrutinib exposure may occur resulting in decreased acalabrutinib effectiveness. Consider using an antacid or H2-blocker if acid suppression therapy is needed.
Separate the administration of acalabrutinib and antacids by at least 2 hours; give acalabrutinib 2 hours before a H2-blocker. Acalabrutinib solubility decreases with increasing pH values.
Alendronate: Moderate Proton pump inhibitors PPIs are widely used and are frequently coadministered in users of oral bisphosphonates. A national register-based, open cohort study of 38, elderly patients suggests that those who use proton pump inhibitors in conjunction with alendronate have a dose-dependent loss of protection against hip fracture. While causality was not investigated, the dose-response relationship noted during the study suggested that PPIs may reduce oral alendronate efficacy, perhaps through an effect on absorption or other mechanism, and therefore PPIs may not be optimal agents to control gastrointestinal complaints.
It is not yet clear if all bisphosphonates would exhibit a loss of efficacy when PPIs are coadministered, but the results suggest that the interaction may occur across the class.
Alendronate; Cholecalciferol: Moderate Proton pump inhibitors PPIs are widely used and are frequently coadministered in users of oral bisphosphonates. Hypomagnesemia occurs with thiazide diuretics chlorothiazide, hydrochlorothiazide, indapamide, and metolazone. Low serum magnesium may lead to serious adverse events such as muscle spasm, seizures, and arrhythmias. Therefore, clinicians should monitor serum magnesium concentrations periodically in patients taking a PPI and diuretics concomitantly.
Patients who develop hypomagnesemia may require PPI discontinuation in addition to magnesium replacement. Amobarbital: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary. The time to maximum concentration Tmax of amphetamines is decreased compared to when administered alone, thus increasing amphetamine concentrations and exposure, which may be of particular significance with extended-release dosage forms.
Monitor clinical response and adjust if needed. Some extended-release dosage forms of amphetamine or dextroamphetamine salts should not be given with PPIs. The concomitant use of PPIs with some extended-release dosage forms may result in amphetamine dose-dumping. Ampicillin: Major Proton pump inhibitors PPIs have long-lasting effects on the secretion of gastric acid.
For enteral ampicillin, whose bioavailability is influenced by gastric pH, the concomitant administration of PPIs can exert a significant effect on ampicillin absorption.
Significantly more subjects treated with lansoprazole also reported no night-time heartburn and no heartburn during day 1 of the day treatment. Adverse events were infrequent and were similar for lansoprazole and placebo groups.
0コメント